{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:56:57Z","timestamp":1794873417397,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013117","name":"International Fibrodysplasia Ossificans Progressiva Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heterotopic ossification is the most disabling feature of fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder for which there is currently no prevention or treatment. Most patients with this disease harbor a heterozygous activating mutation (c.617\u2009G\u2009&gt;\u2009A;p.R206H) in ACVR1. Here, we identify recombinant AAV9 as the most effective serotype for transduction of the major cells-of-origin of heterotopic ossification. We use AAV9 delivery for gene replacement by expression of codon-optimized human ACVR1, ACVR1R206H allele-specific silencing by AAV-compatible artificial miRNA and a combination of gene replacement and silencing. In mouse skeletal cells harboring a conditional knock-in allele of human mutant ACVR1 and in patient-derived induced pluripotent stem cells, AAV gene therapy ablated aberrant Activin A signaling and chondrogenic and osteogenic differentiation. In Acvr1(R206H) knock-in mice treated locally in early adulthood or systemically at birth, trauma-induced endochondral bone formation was markedly reduced, while inflammation and fibroproliferative responses remained largely intact in the injured muscle. Remarkably, spontaneous heterotopic ossification also substantially decreased in in Acvr1(R206H) knock-in mice treated systemically at birth or in early adulthood. Collectively, we develop promising gene therapeutics that can prevent disabling heterotopic ossification in mice, supporting clinical translation to patients with fibrodysplasia ossificans progressiva.<\/jats:p>","DOI":"10.1038\/s41467-022-33956-9","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T23:28:00Z","timestamp":1666135680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery"],"prefix":"10.1038","volume":"13","author":[{"given":"Yeon-Suk","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9072-4293","authenticated-orcid":false,"given":"Jung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-1567","authenticated-orcid":false,"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-2034","authenticated-orcid":false,"given":"Sachin","family":"Chaugule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-106X","authenticated-orcid":false,"given":"Edward","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyoung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyonho","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6971","authenticated-orcid":false,"given":"Eileen M.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-9012","authenticated-orcid":false,"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4947-3293","authenticated-orcid":false,"given":"Jae-Hyuck","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"33956_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo, R. J. et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J. Rare Dis. 16, 350 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"33956_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan, F. S. et al. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 22, 191\u2013205 (2008).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"33956_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bone.2008.05.013","volume":"43","author":"EM Shore","year":"2008","unstructured":"Shore, E. M. & Kaplan, F. S. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone 43, 427\u2013433 (2008).","journal-title":"Bone"},{"key":"33956_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore, E. M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525\u2013527 (2006).","journal-title":"Nat. Genet."},{"key":"33956_CR5","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino, K. et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc. Natl Acad. Sci. USA 112, 15438\u201315443 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33956_CR6","doi-asserted-by":"crossref","unstructured":"Aykul, S. et al. Activin A forms a non-signaling complex with ACVR1 and type II Activin\/BMP receptors via its finger 2 tip loop. Elife 9, e54582 (2020).","DOI":"10.7554\/eLife.54582"},{"key":"33956_CR7","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell, S. J. et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. 7, 303ra137 (2015).","journal-title":"Sci. Transl. Med."},{"key":"33956_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","volume":"109","author":"DM Alessi Wolken","year":"2018","unstructured":"Alessi Wolken, D. M., Idone, V., Hatsell, S. J., Yu, P. B. & Economides, A. N. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone 109, 210\u2013217 (2018).","journal-title":"Bone"},{"key":"33956_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2106\/JBJS.H.01177","volume":"91","author":"VY Lounev","year":"2009","unstructured":"Lounev, V. Y. et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Jt. Surg. Am. 91, 652\u2013663 (2009).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"33956_CR10","doi-asserted-by":"publisher","first-page":"366ra163","DOI":"10.1126\/scitranslmed.aaf1090","volume":"8","author":"D Dey","year":"2016","unstructured":"Dey, D. et al. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci. Transl. Med. 8, 366ra163 (2016).","journal-title":"Sci. Transl. Med."},{"key":"33956_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02872-2","volume":"9","author":"JB Lees-Shepard","year":"2018","unstructured":"Lees-Shepard, J. B. et al. Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva. Nat. Commun. 9, 471 (2018).","journal-title":"Nat. Commun."},{"key":"33956_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bone.2018.01.029","volume":"109","author":"JB Lees-Shepard","year":"2018","unstructured":"Lees-Shepard, J. B. & Goldhamer, D. J. Stem cells and heterotopic ossification: Lessons from animal models. Bone 109, 178\u2013186 (2018).","journal-title":"Bone"},{"issue":"Suppl. 2","key":"33956_CR13","first-page":"437","volume":"10","author":"RJ Pignolo","year":"2013","unstructured":"Pignolo, R. J., Shore, E. M. & Kaplan, F. S. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr. Endocrinol. Rev. 10(Suppl. 2), 437\u2013448 (2013).","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"33956_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bcp.13823","volume":"85","author":"KL Wentworth","year":"2019","unstructured":"Wentworth, K. L., Masharani, U. & Hsiao, E. C. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br. J. Clin. Pharm. 85, 1180\u20131187 (2019).","journal-title":"Br. J. Clin. Pharm."},{"key":"33956_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 6, 53 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"33956_CR16","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.omtm.2020.04.010","volume":"17","author":"YS Yang","year":"2020","unstructured":"Yang, Y. S. et al. Bone-targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy. Mol. Ther. Methods Clin. Dev. 17, 922\u2013935 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"33956_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10809-6","volume":"10","author":"YS Yang","year":"2019","unstructured":"Yang, Y. S. et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat. Commun. 10, 2958 (2019).","journal-title":"Nat. Commun."},{"key":"33956_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymthe.2020.01.007","volume":"28","author":"RW Herzog","year":"2020","unstructured":"Herzog, R. W. Encouraging and unsettling findings in long-term follow-up of AAV gene transfer. Mol. Ther. 28, 341\u2013342 (2020).","journal-title":"Mol. Ther."},{"key":"33956_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","volume":"20","author":"A Asokan","year":"2012","unstructured":"Asokan, A., Schaffer, D. V. & Samulski, R. J. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699\u2013708 (2012).","journal-title":"Mol. Ther."},{"key":"33956_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature04791","volume":"441","author":"D Grimm","year":"2006","unstructured":"Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways. Nature 441, 537\u2013541 (2006).","journal-title":"Nature"},{"key":"33956_CR21","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride, J. L. et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 105, 5868\u20135873 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33956_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ymthe.2019.11.018","volume":"28","author":"J Xie","year":"2020","unstructured":"Xie, J. et al. Effective and accurate gene silencing by a recombinant AAV-compatible MicroRNA scaffold. Mol. Ther. 28, 422\u2013430 (2020).","journal-title":"Mol. Ther."},{"key":"33956_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1089\/hum.2010.005","volume":"21","author":"M Li","year":"2010","unstructured":"Li, M. et al. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum. Gene Ther. 21, 1527\u20131543 (2010).","journal-title":"Hum. Gene Ther."},{"key":"33956_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2018.04.005","volume":"9","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout, L. P. et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Mol. Ther. Methods Clin. Dev. 9, 323\u2013329 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"33956_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","volume":"14","author":"B Balakrishnan","year":"2014","unstructured":"Balakrishnan, B. & Jayandharan, G. R. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr. Gene Ther. 14, 86\u2013100 (2014).","journal-title":"Curr. Gene Ther."},{"key":"33956_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13287-016-0372-6","volume":"7","author":"E Barruet","year":"2016","unstructured":"Barruet, E. et al. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1\/5\/8 signaling. Stem Cell Res. Ther. 7, 115 (2016).","journal-title":"Stem Cell Res. Ther."},{"key":"33956_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-190","volume":"8","author":"Y Matsumoto","year":"2013","unstructured":"Matsumoto, Y. et al. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J. Rare Dis. 8, 190 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"33956_CR28","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.1073\/pnas.1906512116","volume":"116","author":"SY Min","year":"2019","unstructured":"Min, S. Y. et al. Diverse repertoire of human adipocyte subtypes develops from transcriptionally distinct mesenchymal progenitor cells. Proc. Natl Acad. Sci. USA 116, 17970\u201317979 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33956_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/ten.tea.2018.0067","volume":"25","author":"R Rojas-Rodriguez","year":"2019","unstructured":"Rojas-Rodriguez, R. et al. Generation of functional human adipose tissue in mice from primed progenitor cells. Tissue Eng. Part A 25, 842\u2013854 (2019).","journal-title":"Tissue Eng. Part A"},{"key":"33956_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bone.2017.07.003","volume":"109","author":"E Barruet","year":"2018","unstructured":"Barruet, E. & Hsiao, E. C. Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva. Bone 109, 162\u2013167 (2018).","journal-title":"Bone"},{"key":"33956_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bone.2016.01.004","volume":"84","author":"D Micha","year":"2016","unstructured":"Micha, D. et al. Inhibition of TGFbeta signaling decreases osteogenic differentiation of fibrodysplasia ossificans progressiva fibroblasts in a novel in vitro model of the disease. Bone 84, 169\u2013180 (2016).","journal-title":"Bone"},{"key":"33956_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bone.2017.07.007","volume":"109","author":"TJ de Vries","year":"2018","unstructured":"de Vries, T. J. et al. Periodontal ligament fibroblasts as a cell model to study osteogenesis and osteoclastogenesis in fibrodysplasia ossificans progressiva. Bone 109, 168\u2013177 (2018).","journal-title":"Bone"},{"key":"33956_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828\u2013834 (2004).","journal-title":"Nat. Med."},{"key":"33956_CR34","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.celrep.2019.03.105","volume":"27","author":"JM Goldstein","year":"2019","unstructured":"Goldstein, J. M. et al. In situ modification of tissue stem and progenitor cell genomes. Cell Rep. 27, 1254\u20131264 e1257 (2019).","journal-title":"Cell Rep."},{"key":"33956_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo, R. J. et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J. Bone Min. Res 31, 650\u2013656 (2016).","journal-title":"J. Bone Min. Res"},{"key":"33956_CR36","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.4049\/jimmunol.1302743","volume":"192","author":"SJ Heine","year":"2014","unstructured":"Heine, S. J. et al. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J. Immunol. 192, 1630\u20131640 (2014).","journal-title":"J. Immunol."},{"key":"33956_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jor.22500","volume":"32","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. A novel mouse model of trauma induced heterotopic ossification. J. Orthop. Res. 32, 183\u2013188 (2014).","journal-title":"J. Orthop. Res."},{"key":"33956_CR38","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1177\/0363546508322886","volume":"36","author":"M Nozaki","year":"2008","unstructured":"Nozaki, M. et al. Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth. Am. J. Sports Med. 36, 2354\u20132362 (2008).","journal-title":"Am. J. Sports Med."},{"key":"33956_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/jbmr.1562","volume":"27","author":"MN Wosczyna","year":"2012","unstructured":"Wosczyna, M. N., Biswas, A. A., Cogswell, C. A. & Goldhamer, D. J. Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J. Bone Min. Res. 27, 1004\u20131017 (2012).","journal-title":"J. Bone Min. Res."},{"key":"33956_CR40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1242\/dmm.010280","volume":"5","author":"FS Kaplan","year":"2012","unstructured":"Kaplan, F. S., Chakkalakal, S. A. & Shore, E. M. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis. Model Mech. 5, 756\u2013762 (2012).","journal-title":"Dis. Model Mech."},{"key":"33956_CR41","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/jbmr.1637","volume":"27","author":"SA Chakkalakal","year":"2012","unstructured":"Chakkalakal, S. A. et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J. Bone Min. Res. 27, 1746\u20131756 (2012).","journal-title":"J. Bone Min. Res."},{"key":"33956_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.161","volume":"5","author":"A Uezumi","year":"2014","unstructured":"Uezumi, A. et al. Identification and characterization of PDGFRalpha+ mesenchymal progenitors in human skeletal muscle. Cell Death Dis. 5, e1186 (2014).","journal-title":"Cell Death Dis."},{"key":"33956_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2106\/00004623-200702000-00017","volume":"89","author":"FS Kaplan","year":"2007","unstructured":"Kaplan, F. S. et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Jt. Surg. Am. 89, 347\u2013357 (2007).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"33956_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jbmr.3304","volume":"33","author":"MR Convente","year":"2018","unstructured":"Convente, M. R. et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1(R206H) mouse model of fibrodysplasia ossificans progressiva. J. Bone Min. Res. 33, 269\u2013282 (2018).","journal-title":"J. Bone Min. Res."},{"key":"33956_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","volume":"188","author":"M Hahne","year":"1998","unstructured":"Hahne, M. et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188, 1185\u20131190 (1998).","journal-title":"J. Exp. Med."},{"key":"33956_CR46","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1189\/jlb.0410226","volume":"88","author":"T Putoczki","year":"2010","unstructured":"Putoczki, T. & Ernst, M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109\u20131117 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"33956_CR47","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L","volume":"31","author":"M Vulcano","year":"2001","unstructured":"Vulcano, M. et al. Dendritic cells as a major source of macrophage-derived chemokine\/CCL22 in vitro and in vivo. Eur. J. Immunol. 31, 812\u2013822 (2001).","journal-title":"Eur. J. Immunol."},{"key":"33956_CR48","doi-asserted-by":"publisher","unstructured":"Brouxhon, S. M., O\u2019Banion, M. K. & Kyrkanides, S. AAV gene therapy vectors in the TMJ. Clin. Exp. Dent. Res. https:\/\/doi.org\/10.1002\/cre2.636 (2022).","DOI":"10.1002\/cre2.636"},{"key":"33956_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03240-2","volume":"21","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-gamma agonist palovarotene: a case report. BMC Musculoskelet. Disord. 21, 204 (2020).","journal-title":"BMC Musculoskelet. Disord."},{"key":"33956_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/dvdy.20197","volume":"232","author":"X Xu","year":"2005","unstructured":"Xu, X., Bringas, P. Jr., Soriano, P. & Chai, Y. PDGFR-alpha signaling is critical for tooth cusp and palate morphogenesis. Dev. Dyn. 232, 75\u201384 (2005).","journal-title":"Dev. Dyn."},{"key":"33956_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/gene.10170","volume":"35","author":"TL Sreenath","year":"2003","unstructured":"Sreenath, T. L., Cho, A., Thyagarajan, T. & Kulkarni, A. B. Odontoblast-specific expression of cre recombinase successfully deletes gene segments flanked by loxP sites in mouse teeth. Genesis 35, 94\u201399 (2003).","journal-title":"Genesis"},{"key":"33956_CR52","doi-asserted-by":"crossref","unstructured":"Lees-Shepard, J. B. et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife 7, e40814 (2018).","DOI":"10.7554\/eLife.40814"},{"key":"33956_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan, F. S. et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30, 379\u2013390 (2009).","journal-title":"Hum. Mutat."},{"key":"33956_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ydbio.2020.11.004","volume":"470","author":"OW Towler","year":"2021","unstructured":"Towler, O. W., Peck, S. H., Kaplan, F. S. & Shore, E. M. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Dev. Biol. 470, 136\u2013146 (2021).","journal-title":"Dev. Biol."},{"key":"33956_CR55","doi-asserted-by":"crossref","unstructured":"Barruet, E. et al. NF-kappaB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight 3, e122958 (2018).","DOI":"10.1172\/jci.insight.122958"},{"key":"33956_CR56","doi-asserted-by":"crossref","unstructured":"Pignolo, R. J. et al. Plasma-soluble biomarkers for fibrodysplasia ossificans progressiva (FOP) reflect acute and chronic inflammatory states. J. Bone Miner. Res. 37, 475\u2013483 (2021).","DOI":"10.1002\/jbmr.4492"},{"key":"33956_CR57","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.bone.2021.116129","volume":"153","author":"K Matsuo","year":"2021","unstructured":"Matsuo, K. et al. ACVR1(R206H) extends inflammatory responses in human induced pluripotent stem cell-derived macrophages. Bone 153, 116129 (2021).","journal-title":"Bone"},{"key":"33956_CR58","doi-asserted-by":"crossref","unstructured":"Eekhoff, E. M. W. et al. Gene therapy for Fibrodysplasia Ossificans Progressiva (FOP): feasibility and obstacles. Hum. Gene Ther. 33, 782\u2013788 (2022).","DOI":"10.1089\/hum.2022.023"},{"key":"33956_CR59","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier, A. C. et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97, 1635\u20131644 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"33956_CR60","doi-asserted-by":"crossref","unstructured":"Chiu, W. et al. An Update on gene therapy for inherited retinal dystrophy: experience in Leber congenital amaurosis clinical trials. Int. J. Mol. Sci. 22, 4534 (2021).","DOI":"10.3390\/ijms22094534"},{"key":"33956_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"key":"33956_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"33956_CR63","first-page":"128","volume":"10","author":"B Blits","year":"2016","unstructured":"Blits, B. & Petry, H. Perspective on the road toward gene therapy for Parkinson\u2019s disease. Front. Neuroanat. 10, 128 (2016).","journal-title":"Front. Neuroanat."},{"key":"33956_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","volume":"383","author":"C Mueller","year":"2020","unstructured":"Mueller, C. et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 383, 151\u2013158 (2020).","journal-title":"N. Engl. J. Med."},{"key":"33956_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"R Pattali","year":"2019","unstructured":"Pattali, R., Mou, Y. & Li, X. J. AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther. 26, 287\u2013295 (2019).","journal-title":"Gene Ther."},{"key":"33956_CR66","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/hum.2017.095","volume":"29","author":"K Kodippili","year":"2018","unstructured":"Kodippili, K. et al. Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb Mini-dystrophin gene in the canine model. Hum. Genet. Ther. 29, 299\u2013311 (2018).","journal-title":"Hum. Genet. Ther."},{"key":"33956_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59\u201365 (2009).","journal-title":"Nat. Biotechnol."},{"key":"33956_CR68","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/hum.2008.123","volume":"19","author":"LT Bish","year":"2008","unstructured":"Bish, L. T. et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359\u20131368 (2008).","journal-title":"Hum. Gene Ther."},{"key":"33956_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451\u2013456 (2014).","journal-title":"Nat. Genet."},{"key":"33956_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46, 457\u2013461 (2014).","journal-title":"Nat. Genet."},{"key":"33956_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s42003-019-0420-8","volume":"2","author":"D Carvalho","year":"2019","unstructured":"Carvalho, D. et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun. Biol. 2, 156 (2019).","journal-title":"Commun. Biol."},{"key":"33956_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bone.2017.09.004","volume":"109","author":"E Williams","year":"2018","unstructured":"Williams, E. & Bullock, A. N. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone 109, 251\u2013258 (2018).","journal-title":"Bone"},{"key":"33956_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08823-9","volume":"10","author":"CM Hoeman","year":"2019","unstructured":"Hoeman, C. M. et al. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nat. Commun. 10, 1023 (2019).","journal-title":"Nat. Commun."},{"key":"33956_CR74","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh, P. B. et al. Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum. Gene Ther. 31, 787 (2020).","journal-title":"Hum. Gene Ther."},{"key":"33956_CR75","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","volume":"23","author":"M Arjomandnejad","year":"2021","unstructured":"Arjomandnejad, M. et al. Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells. Mol. Ther. Methods Clin. Dev. 23, 490\u2013506 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"33956_CR76","doi-asserted-by":"publisher","first-page":"22542","DOI":"10.1074\/jbc.M109.094557","volume":"285","author":"GA Song","year":"2010","unstructured":"Song, G. A. et al. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 285, 22542\u201322553 (2010).","journal-title":"J. Biol. Chem."},{"key":"33956_CR77","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.ymthe.2017.03.028","volume":"25","author":"J Xie","year":"2017","unstructured":"Xie, J. et al. Short DNA hairpins compromise recombinant adeno-associated virus genome homogeneity. Mol. Ther. 25, 1363\u20131374 (2017).","journal-title":"Mol. Ther."},{"key":"33956_CR78","first-page":"1209","volume":"2","author":"G Gao","year":"2012","unstructured":"Gao, G. & Sena-Esteves, M. Introducing genes into mammalian cells: viral vectors. Mol. Cloning 2, 1209\u20131313 (2012).","journal-title":"Mol. Cloning"},{"key":"33956_CR79","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nprot.2008.95","volume":"3","author":"M Gosset","year":"2008","unstructured":"Gosset, M., Berenbaum, F., Thirion, S. & Jacques, C. Primary culture and phenotyping of murine chondrocytes. Nat. Protoc. 3, 1253\u20131260 (2008).","journal-title":"Nat. Protoc."},{"key":"33956_CR80","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"33956_CR81","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nmeth.1591","volume":"8","author":"K Okita","year":"2011","unstructured":"Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409\u2013412 (2011).","journal-title":"Nat. Methods"},{"key":"33956_CR82","doi-asserted-by":"crossref","unstructured":"Lyu, H., Elkins, C. M., Pierce, J. L., Serezani, C. H. & Perrien, D. S. MyD88 is not required for muscle injury-induced endochondral heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Biomedicines 9, 630 (2021).","DOI":"10.3390\/biomedicines9060630"},{"key":"33956_CR83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ab.2004.02.002","volume":"329","author":"CA Gregory","year":"2004","unstructured":"Gregory, C. A., Gunn, W. G., Peister, A. & Prockop, D. J. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal. Biochem. 329, 77\u201384 (2004).","journal-title":"Anal. Biochem."},{"key":"33956_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"33956_CR85","doi-asserted-by":"publisher","first-page":"11 14 11","DOI":"10.1002\/0471250953.bi1114s51","volume":"51","author":"A Dobin","year":"2015","unstructured":"Dobin, A. & Gingeras, T. R. Mapping RNA-seq Reads with STAR. Curr. Protoc. Bioinforma. 51, 11 14 11\u201311 14 19 (2015).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"33956_CR86","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"33956_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"33956_CR88","first-page":"275","volume":"18","author":"M Stephens","year":"2017","unstructured":"Stephens, M. False discovery rates: a new deal. Biostatistics 18, 275\u2013294 (2017).","journal-title":"Biostatistics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33956-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:03:17Z","timestamp":1666137797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33956-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33956"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33956-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1646941\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.G. and J.-H.S. have submitted a patent application concerning the methodology described in this study. G.G. and J.-H.S. are scientific co-founders of AAVAA Therapeutics and hold equity in this company. G.G. is also a scientific co-founder of Voyager Therapeutics and Aspa Therapeutics and holds equity in these companies. G.G. is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Aspa Therapeutics Inc., and other biopharmaceutical companies. E.C.H. serves in a volunteer capacity on the registry advisory board of the IFOPA; on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. E.C.H. received prior research support through his institution from Regeneron Pharmaceuticals. E.C.H. receives clinical trials research support through his institution from Clementia, an Ipsen company. F.S.K. is the founder and past-President of the International Clinical Council (ICC) on FOP. F.S.K. serves in a volunteer capacity on the registry advisory board of the IFOPA. F.S.K. is an investigator on clinical trials sponsored by Clementia, an Ipsen company, and by Regeneron Pharmaceuticals. E.M.S. serves in a volunteer capacity as a research advisor to the IFOPA. These pose no competing interests for this study. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6175"}}